amoxicillin

(redirected from amoxicillin-clavulanic acid)
Also found in: Dictionary, Thesaurus, Acronyms.
Related to amoxicillin-clavulanic acid: Augmentin, Amoxiclav

amoxicillin

 [ah-moks″ĭ-sil´in]
an antibiotic that is a penicillin analogue similar in action to ampicillin but more efficiently absorbed from the gastrointestinal tract and therefore requiring less frequent dosage and not as likely to cause diarrhea.

a·mox·i·cil·lin

(ă-mok'si-sil'in),
A semisynthetic penicillin antibiotic with an antimicrobial spectrum similar to that of ampicillin.

amoxicillin

/amox·i·cil·lin/ (ah-mok″sĭ-sil´in) a semisynthetic derivative of ampicillin effective against a broad spectrum of gram-positive and gram-negative bacteria.

amoxicillin

(ə-mŏk′sĭ-sĭl′ĭn)
n.
A semisynthetic penicillin, C16H19N3O5S, having an antibacterial spectrum of action similar to that of ampicillin.

amoxicillin

[əmok′səsil′in]
a beta-lactam semisynthetic oral penicillin antibiotic.
indication It is prescribed in the treatment of infections caused by a susceptible gram-negative or gram-positive bacteria.
contraindication Known hypersensitivity to any penicillin prohibits its use.
adverse effects Among the most serious adverse reactions are anaphylaxis, nausea, and diarrhea. Allergic reactions and rashes are common.

amoxicillin

Infectious disease A broad-spectrum semisynthetic penicillin with activity similar to that of ampicillin

amoxicillin

Amoxycillin, an AMPICILLIN-like penicillin antibiotic, effective in TYPHOID and many other infections. Brand names are Amoxil and Galenamox. Compounded with lansoprazol and clarithromycin it is marketed as Heliclear.

amoxicillin

penicillin antibiotic of similar action to ampicillin; usually administered as 250 mg by mouth every 8 hours (125 mg every 8 hours for a child) for soft-tissue infections

a·mox·i·cil·lin

(ă-mok'si-sil'in)
A semisynthetic penicillin antibiotic with an antimicrobial spectrum similar to that of ampicillin.

amoxicillin, amoxycillin

an aminopenicillin, similar in action to ampicillin and susceptible to β-lactamase, but more efficiently absorbed from the gastrointestinal tract and with a longer duration of action.

amoxicillin-clavulanic acid
addition of clavulanic acid widens the spectrum of activity and renders amoxicillin resistant to β-lactamase. A widely used antibiotic in dogs and cats.
References in periodicals archive ?
002 (#) * Salmonella Newport-multidrug-resistant AmpC (MDRAmpC) is resistant to at least chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole, tetracycline, amoxicillin-clavulanic acid, ampicillin, cefoxitin, ceftiofur, and cephalothin and shows decreased susceptibility to ceftriaxone.
Only 4 Salmonella Newport isolates from stranded seals were resistant to antimicrobial drugs; 3 isolates were resistant to ampicillin, with intermediate resistance to ticarcillin-clavulanic acid, and 1 isolate was resistant to amoxicillin-clavulanic acid and cefazolin.
Typhimurium R-type ACSSuT isolates, 15 (7%) were also resistant to amoxicillin-clavulanic acid, 4 (2%) were resistant to nalidixic acid, 3 (1%) were resistant to cephalothin, 2 (1%) were resistant to trimethoprim, 2 (1%) were resistant to gentamicin, 1 was resistant to ceftiofur, and 1 was resistant to ceftriaxone.
cloacae isolate was susceptible to piperacillin, piperacillin-tazobactam, ceftazidime, ceftriaxone, cefepime, ciprofloxacin, gentamicin, aztreonam, and trimethoprim-sulfamethoxazole and was resistant to ampicillin, amoxicillin-clavulanic acid, cefazolin, and cefoxitin.
Strains producing ESBL were defined as strains showing synergism between amoxicillin-clavulanic acid and cefotaxime, ceftazidime, cefepime, or aztreonam (4,5).
Approximately 50% of the 137 isolates from humans were resistant to ampicillin, sulfamethoxazole, cephalothin, tetracycline, or streptomycin, and approximately 25% were resistant to chloramphenicol, trimethoprim-sulfamethoxazole, or amoxicillin-clavulanic acid.
Fifty-nine percent of isolates from humans were resistant to sulfamethoxazole, 59% to streptomycin, 56% to ampicillin, 56% to tetracycline, 50% to cephalothin, 38% to trimethoprim-sulfamethoxazole, 34% to chloramphenicol, and 18% to amoxicillin-clavulanic acid (Figure 1A).
Of 23 isolates resistant to cefoxitin, 91% were resistant to amoxicillin-clavulanic acid.
However, because these two isolates also displayed resistance or decreased susceptibility to other [beta]-lactam antimicrobials, including ampicillin, amoxicillin-clavulanic acid, cephalothin, cefoxitin, and ceftriaxone, ceftiofur-resistance in these isolates might have resulted from of [beta]-lactam use in clinical medicine.